Novozymes: Bioenergy was probably the most exposed

Although the result booked for Novozymes' Bioenergy division in Q1 2021 was impacted by Covid-19 in the US, it was boosted from elsewhere, says company CFO, cementing growth expectations for the coming months.

Photo: PR / Novozymes

Most of the past year has been marked by the pandemic, and although this is 2021 the Covid crisis is still a reality amid expectations that vaccines and lifted restrictions might provide a return to our daily lives.

And the wait is also putting pressure on Novozymes' sales of enzymes for bioethanol production in its Bioenergy division. But there is improvement ahead, says Chief Financial Officer Lars Green.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from EnergyWatch

Further reading

Related articles

Latest News

See all jobs